← Leaderboards
Martin K Safo
Virginia Commonwealth University
$4,719,250
Attributed
$5,573,028
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2006–23$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,573,028 · 8
By mechanism
R01$2,441,438 · 2
R61$1,135,267 · 1
S10$600,000 · 1
R33$572,290 · 1
R21$403,269 · 1
K01$268,264 · 1
Top collaborators
- Osheiza Y Abdulmalik3 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Paulina A Essah$945,136
- Paul Dent$11,860,656
- Michael A McVoy$9,920,342
- Tarynn Madysyn Witten$878,366
- John D Roberts$6,720,279
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelSickle Cell AnemiaHemoglobinLeadIn VitroDesignStructurePreventInsightBaseExhibitsBiologicalAffinityModificationNovel TherapeuticsIn VivoAldehydesHemolysisHydroxyureaHealth DisparityAcuteErythrocytesInflammationAntisickling Agents
Grant awards (20)
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy$572,290
R33 · FY2023 · HL · contact PI
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy$559,674
R61 · FY2022 · HL · contact PI
Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy$575,593
R61 · FY2021 · HL · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$395,860
R01 · FY2018 · MD · contact PI
X-ray Crystallographic Data Collection System$600,000
S10 · FY2017 · OD · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$395,862
R01 · FY2017 · MD · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$25,474
R01 · FY2017 · MD · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$395,866
R01 · FY2016 · MD · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$78,708
R01 · FY2016 · MD · contact PI
Structure of cytomegalovirus nuclease, UL98$76,250
R03 · FY2016 · AI · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$395,869
R01 · FY2015 · MD · contact PI
Structure of cytomegalovirus nuclease, UL98$76,250
R03 · FY2015 · AI · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$53,235
R01 · FY2015 · MD · contact PI
Hemoglobin Modifiers for Sickle Cell Disease Therapy$408,997
R01 · FY2014 · MD · contact PI
Rational Design of Novel Estrogen Receptor Antagonists$291,567
R01 · FY2007 · CA · contact PI
Structure of Beta-lactam resistance regulators$217,019
R21 · FY2007 · AI · contact PI
Structure of Beta-lactam resistance regulators$186,250
R21 · FY2006 · AI · contact PI
RATIONAL DESIGN OF ANTISICKLING AGENTS$90,163
K01 · FY2002 · HL
RATIONAL DESIGN OF ANTISICKLING AGENTS$88,521
K01 · FY2001 · HL
RATIONAL DESIGN OF ANTISICKLING AGENTS$89,580
K01 · FY2000 · HL